Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
AtriCure Inc(ATRC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ATRC
09/25/2026: ATRC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
AtriCure Inc is a specialized medical device company that develops surgical solutions for atrial fibrillation and left atrial appendage management. The company has a leading position in surgical ablation, supported by a strong physician training model and documented clinical evidence. Its primary investment story centers on the continued penetration of its AtriClip system and the growth of its cardiac surgery technologies. However, the company faces risks from competing catheter-based technologies and the inherent challenges of growing as a specialized medical device firm. AtriCure may suit growth-oriented investors looking for exposure to surgical innovation, while those concerned with valuation or volatility should monitor clinical data readouts and competitive market shifts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company targets high-growth segments in cardiac surgery with specialized, innovative technology. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data readouts and consistent quarterly revenue outperformance. |
| Value investor | Weak fit | The company is typically priced for growth rather than traditional value metrics like P/E ratios. |
| Dividend investor | Weak fit | AtriCure does not pay a dividend, prioritizing reinvestment in product development. |
| Low-risk investor | Weak fit | Small-cap medtech stocks often exhibit high volatility related to clinical trials and regulatory outcomes. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a smaller player in the medtech space, the stock is prone to sharp swings based on earnings and clinical results. |
| Valuation risk | Medium / high | Investors often pay a premium for growth, which can lead to corrections if growth targets are missed. |
| Competition risk (Medtronic/Abbott) | High | Larger competitors with greater resources can influence market access and physician behavior. |
| Business quality | Medium | The company possesses strong, specialized technology, though it lacks the broad diversification of industry giants. |
| Dividend income | Low / none | Investors receive no current income from dividends. |
| Execution risk | Medium | Successfully managing large-scale clinical trials and commercializing new products is execution-intensive. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -13.36% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.09B USD | Price to earnings Ratio 289.38 | 1Y Target Price 53.33 |
Price to earnings Ratio 289.38 | 1Y Target Price 53.33 | ||
Volume (30-day avg) 1.3M shares | Beta 1.26 | 52 Weeks Range 25.36 - 61.70 | Updated Date 09/24/2026 |
52 Weeks Range 25.36 - 61.70 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cardiac Ablation | Radiofrequency and cryoablation devices used in open-heart and minimally invasive surgeries. | Revenue is driven by the sale of disposable devices used during every procedure. |
| Appendage Management | AtriClip and related products to treat the left atrial appendage. | This is a recurring revenue driver as surgeons adopt the procedure for stroke prevention. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 289.38 | Forward PE 232.56 | Enterprise Value 2.95B | Price to Sales(TTM) 5.43 |
Enterprise Value 2.95B | Price to Sales(TTM) 5.43 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA 75.06 | Shares Outstanding 50.87M | Shares Floating 48.82M |
Shares Outstanding 50.87M | Shares Floating 48.82M | ||
Percent Insiders 3.77 | Percent Institutions 105.58 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About AtriCure Inc
Exchange NASDAQ | Headquarters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1350 | Website https://www.atricure.com |
Full time employees 1350 | Website https://www.atricure.com | ||
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.